Univariate analysis of the effect of genomic complexity on TTFT or TTST estimates, hazard ratios, and significance levels
| . | Previously untreated patients . | Previously treated patients . | ||||
|---|---|---|---|---|---|---|
| Median TTFT, mo . | Hazard ratio . | Significance level . | Median TTST, mo . | Hazard ratio . | Significance level . | |
| Genomic complexity (visual) | ||||||
| 1.5 or more | Not reached | 1.5 | .26 | 19 | 1.1 | .81 |
| 2.0 or more | Not reached | 1.6 | .17 | 20 | 1.2 | .64 |
| 2.5 or more | 31 | 3.7 | <.001 | 14 | 2 | .07 |
| 3.0 or more | 25 | 4.3 | <.001 | 7 | 3.4 | <.001 |
| 3.5 or more | 23 | 4.7 | <.001 | 3 | 3.6 | <.001 |
| Genomic complexity (visual losses) | ||||||
| 1.5 or more | 81 | 2.3 | .01 | 18 | 1.8 | .13 |
| 2.0 or more | 79 | 2.3 | .01 | 15 | 2 | .06 |
| 2.5 or more | 23 | 4.3 | <.001 | 8 | 2.6 | .01 |
| 3.0 or more | 14 | 5.4 | <.001 | 6 | 3.1 | <.001 |
| 3.5 or more | 14 | 6.6 | <.001 | 2 | 4.8 | <.001 |
| . | Previously untreated patients . | Previously treated patients . | ||||
|---|---|---|---|---|---|---|
| Median TTFT, mo . | Hazard ratio . | Significance level . | Median TTST, mo . | Hazard ratio . | Significance level . | |
| Genomic complexity (visual) | ||||||
| 1.5 or more | Not reached | 1.5 | .26 | 19 | 1.1 | .81 |
| 2.0 or more | Not reached | 1.6 | .17 | 20 | 1.2 | .64 |
| 2.5 or more | 31 | 3.7 | <.001 | 14 | 2 | .07 |
| 3.0 or more | 25 | 4.3 | <.001 | 7 | 3.4 | <.001 |
| 3.5 or more | 23 | 4.7 | <.001 | 3 | 3.6 | <.001 |
| Genomic complexity (visual losses) | ||||||
| 1.5 or more | 81 | 2.3 | .01 | 18 | 1.8 | .13 |
| 2.0 or more | 79 | 2.3 | .01 | 15 | 2 | .06 |
| 2.5 or more | 23 | 4.3 | <.001 | 8 | 2.6 | .01 |
| 3.0 or more | 14 | 5.4 | <.001 | 6 | 3.1 | <.001 |
| 3.5 or more | 14 | 6.6 | <.001 | 2 | 4.8 | <.001 |
Time to first therapy (TTFT) and time to subsequent therapy (TTST) were the clinical end points used. For univariate analysis, total visual complexity scores and visual complexity scores based on losses only were divided into bins (eg, < n lesions vs ≥ n lesions). The Kaplan-Meier method was used to esitmate the survivor function to first (TTFT) or subsequent (TTST) treatment for each subgroup, and the log-rank test was used to calculate 2-sided P values testing significant differences in the survivor function between subgroups.